Twelve cases of malignant hematopathy treated by combined therapy of hematopoietic stem cell transplantation and Chinese herbal medicine
To evaluate the effect of hematopoietic stem cell transplantation combined with Chinese erbal medicine in treating malignant hematopathy.
Allo-bone marrow transplantation (allo-BMT) or allo-peripheral blood stem cell transplantation (allo-PBSCT), with conditioning regimen of60Co total body irradiation + Cyclophosphamide (TBI+ Cy) or busulfan + cyclophosphamide (Bu + Cy), was used to treat 4 cases of chronic granulocytic leukemia (CGL, 3 of chronic phase and 1 of accelerating phase) and one case of acute non-lymphocytic leukemia (ANLL). And auto-BMT or auto-PBSCT, with conditioning regimen of myleran + cytosino arabinoside + cyclophosphamide (MAC) or MAC+ VP16, was used to treat 7 cases of hematopathy, including 5 cases of ANLL (3 of CR1 and 2 of CR2) and 2 cases of malignant lymphoma (1 of the first occurrence and 1 of relapse). Chinese herbal medicine was given orally to all the 12 patients after transplantation according to TCM Syndrome Differentiation.
All patients were successfully engrafted. Within the median follow-up period of 18 (4-70) months, 1 patient (8.3%) died a transplantation-related death, 3 (25.0%) relapsed and 8 (66.7%) survived free of original disease.
Conclusion: Auto-BMT or auto-PBSCT in
CR1 stage of acute leukemia could reduce the relapse rate, when there was no matched bone marow donor; allo-BMT or allo-PBSCT in chronic stage could result in long-term disease-free survival of patients; Chinese herbal medicine administration in patients of malignant hematopathy after transplantation might reduce the complications and plays certain role in promoting recovery of hematopoietic function.
Key Wordsleukemia lymphoma hematopoietic stem cells transplantation Chinese herbal medicine
Unable to display preview. Download preview PDF.
- 3.Miflin G, Rusell NH, Hutenison RM, et al. Allogenic peripheral blood stem cell transplantation for hematological malignancies—an analysis of kinetics of engraftment and GVHD risk. BMT 1997;19(1):9–13.Google Scholar
- 4.Stone K, Gooley T, Siadak M, et al. Allogenic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft vs host disease. Blood 1997;90: 4705–4718.Google Scholar
- 5.Mehta J, Powles R, Singhal S, et al. Autologous bone marrow transplantation for acute myeloid leukemia in first remission: Identification of modifiable prognostic factors. BMT 1995; 16:499–506.Google Scholar
- 6.Han Mz, Feng Sz, Li Cw. Efficacious analysis of autologous BMT in treating 73 cases of acute leukemia. Chin J Hemat 1998; 19 (8): 422–424.Google Scholar
- 8.Han R. Chemical prevention and pharmaceutical treatment of tumors. Beijing: Beijing Medical University-PUMC Union Press, 1991:719–729.Google Scholar